Viorele Kit
NDC Package 50090-1395-0

11-digit billing NDC: 50090139500 · Billing unit: EA · 1 EA per package

Package Information

Viorele (desogestrel and ethinyl estradiol and ethinyl estradiol) kits is oral contraceptives should not be used in women who currently have the following conditions:•Thrombophlebitis or thromboembolic disorders •A past history of deep vein thrombophlebitis or thromboembolic disorders •Cerebral vascular or coronary artery disease •Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive •Undiagnosed abnormal genital bleeding •Cholestatic jaundice of pregnancy or jaundice with prior pill use •Hepatic adenomas or carcinomas •Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations (see WARNINGS, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT). This formulation utilizes a kit delivery system. Marketed by A-s Medication Solutions, this product is identified by NDC 50090-1395 and is authorized under FDA application ANDA091346.

Identification & Billing

NDC Package Code
50090-1395-0
Package Description
1 KIT in 1 KIT
Product Code
11-Digit Billing Format
50090139500
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk
  • RxCUI: 1252016 - {21 (desogestrel 0.15 MG / ethinyl estradiol 0.02 MG Oral Tablet) / 5 (ethinyl estradiol 0.01 MG Oral Tablet) / 2 (inert ingredients 1 MG Oral Tablet) } Pack [Viorele 28 Day]
  • RxCUI: 1252016 - VIORELE 28 Day Pack
  • RxCUI: 1252016 - Viorele 28 Day Pack
  • RxCUI: 248310 - ethinyl estradiol 0.01 MG Oral Tablet
  • RxCUI: 248310 - ethinyl estradiol 10 MCG Oral Tablet

Clinical Specifications

Proprietary Name
Viorele
Non-Proprietary Name
Desogestrel And Ethinyl Estradiol And Ethinyl Estradiol
Dosage Form
Kit - A packaged collection of related material.
Usage Information
Oral contraceptives should not be used in women who currently have the following conditions:•Thrombophlebitis or thromboembolic disorders •A past history of deep vein thrombophlebitis or thromboembolic disorders •Cerebral vascular or coronary artery disease •Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive •Undiagnosed abnormal genital bleeding •Cholestatic jaundice of pregnancy or jaundice with prior pill use •Hepatic adenomas or carcinomas •Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations (see WARNINGS, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT).

Regulatory & Marketing

Labeler Name
A-s Medication Solutions
Product Type
Human Prescription Drug
FDA Application #
ANDA091346
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-04-2012
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 50090-1395-0 identifies a specific commercial package of 1 kit in 1 kit of Viorele, a human prescription drug labeled by A-s Medication Solutions. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This kit is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by A-s Medication Solutions on April 04, 2012. The current certification is valid through December 31, 2027.

How is this A-s Medication Solutions product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 50090139500. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
50090-1395-0
11-Digit CMS (5-4-2)
50090-1395-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.